IDXG — Interpace Biosciences Balance Sheet
0.000.00%
- $7.29m
- $12.06m
- $40.21m
- 52
- 100
- 77
- 90
Annual balance sheet for Interpace Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 2.32 | 2.77 | 3.06 | 4.83 | 3.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10.3 | 8.03 | 6.16 | 5.03 | 4.98 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 16.5 | 14.1 | 12.2 | 12.2 | 10.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10.7 | 11.7 | 10.4 | 2.92 | 2.65 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 51.5 | 45.7 | 38.4 | 16 | 13 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 17.3 | 18.2 | 15.7 | 14.3 | 17.5 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 29.8 | 28.2 | 34.3 | 32.5 | 28.2 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 21.7 | 17.5 | 4.12 | -16.5 | -15.1 |
Total Liabilities & Shareholders' Equity | 51.5 | 45.7 | 38.4 | 16 | 13 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |